Literature DB >> 29247335

Biomarkers of Cardiac Disease in Duchenne Muscular Dystrophy are Insufficient in the Absence of Clinical Cardiologic and Neurologic Assessment.

Claudia Stöllberger1,2, Josef Finsterer3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29247335     DOI： 10.1007/s00246-017-1790-7

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN： 0172-0643            Impact factor:   1.655


× No keyword cloud information.
  5 in total

Review 1.  Treatment of dystrophin cardiomyopathies.

Authors:  Josef Finsterer; Linda Cripe
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

2.  Interleukin 1 Receptor-Like 1 Protein (ST2) is a Potential Biomarker for Cardiomyopathy in Duchenne Muscular Dystrophy.

Authors:  Julia Anderson; Haeri Seol; Heather Gordish-Dressman; Yetrib Hathout; Christopher F Spurney
Journal:  Pediatr Cardiol       Date:  2017-08-18       Impact factor: 1.655

3.  Left ventricular hypertrabeculation/noncompaction as a cardiac manifestation of Duchenne muscular dystrophy under non-invasive positive-pressure ventilation.

Authors:  Josef Finsterer; Ellen Gelpi; Claudia Stöllberger
Journal:  Acta Cardiol       Date:  2005-08       Impact factor: 1.718

Review 4.  Biomarkers for Heart Failure: An Update for Practitioners of Internal Medicine.

Authors:  Nicholas Wettersten; Alan S Maisel
Journal:  Am J Med       Date:  2016-02-01       Impact factor: 4.965

5.  Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD).

Authors:  V D Nadarajah; M van Putten; A Chaouch; P Garrood; V Straub; H Lochmüller; H B Ginjaar; A M Aartsma-Rus; G J B van Ommen; J T den Dunnen; P A C 't Hoen
Journal:  Neuromuscul Disord       Date:  2011-07-02       Impact factor: 4.296
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.